Program Description
Increased prostate-specific antigen levels can be used to determine which patients are at risk for developing aggressive disease and those who require androgen-deprivation therapy (ADT) as the backbone of systemic therapy. However, long-term ADT can have substantial health effects, such as cardiovascular disease and bone health, which can impact patient quality of life. As new therapies for the treatment of prostate cancer are approved and become available, managed care professionals must assess the cost-effectiveness of new drugs and their potential to improve health-related quality of life for patients with prostate cancer. This webinar will highlight recent data presented at the 2022 American Society of Clinical Oncology Annual Meeting and the managed care implications of changes to the therapeutic landscape of prostate cancer.
Target audience: Managed care pharmacists, oncology pharmacists
Type of activity: Application
Release date: January 25, 2023
Expiration date: March 25, 2023
Time to complete activity: 1.0 hour
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Explore the FDA-approved anti-androgen therapies, immunotherapies, and targeted therapies in the evidence-based management of patients with prostate cancer.
- Analyze recent clinical updates on novel and emerging pharmacotherapeutic approaches in the treatment of prostate cancer presented at the 2022 ASCO Annual Meeting.
- Apply the managed care considerations to appropriately assess and integrate new data to improve the care for patients with prostate cancer.
Bryan Fitzgerald, PharmD, BCOP
Clinical Pharmacy Specialist
Wilmot Cancer Institute
University of Rochester Medical Center
Rochester, New York
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-22-630-L01-P. The activity is available for CE credit through March 25, 2023.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Disclosures
The following contributors have no relevant financial relationships with commercial interests to disclose:
Faculty
Bryan Fitzgerald, PharmD, BCOP
Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Abigail Dill; Susan Pordon; Brianna Winters; and Chloe Taccetta.
An anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms